CDK4 and metastatic neoplasm: The knowledge of these molecular features, along with the clinical benefit observed with CDK4/6 inhibitors (CDK4/6i) in HR+/HER2−–BC, provide a rationale for targeting cell cycle regulators in patients with relapsed or metastatic disease that are generally considered incurable and for which additional effective therapies are needed.